Reactions Weekly

, Volume 1736, Issue 1, pp 38–38 | Cite as


Various toxicities: 8 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective study, 8 patients (7 women and 1 man) aged 37−79 years were described, who developed resistance to various tyrosine kinase inhibitors (TKI) for treatment of epidermal growth factor receptor (EGFR) mutated non small cell lung cancers (NSCLC). Among the eight patients, six patients additionally developed various toxicities due to crizotinib alone or in combination with other TKIs for NSCLC [routes and times to reaction onsets not stated; not all dosages and outcomes stated].

Patient 1: A 67-year-old woman, was diagnosed with EGFR mutated stage IV NSCLC in May 2016. She received therapy with gefitinib, cisplatin and pemetrexed. After administration of the first generation TKI, an in situ hybridisation test for cMET/CEPrevealed presence of clusters....


  1. van Veggel B, et al. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. Lung Cancer 124: 130-134, Oct 2018. Available from: URL: - NetherlandsCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations